Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?

Bone

Volumn 41, Issue 3, 2007, Pages 308-317

  Seeman, E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; RISEDRONIC ACID;

BONE DENSITY; BONE FRAGILITY; BONE REMODELING; BONE STRENGTH; BONE STRESS; BONE STRUCTURE; COMPARATIVE STUDY; CORTICAL BONE; DEMINERALIZATION; DISEASE COURSE; DRUG EFFICACY; FRACTURE; FRACTURE TREATMENT; HORMONE DETERMINATION; HUMAN; HYPOGONADISM; MINERALIZATION; NONHUMAN; OSSIFICATION; OSTEOLYSIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; TREATMENT OUTCOME;

ANIMALS; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CLINICAL TRIALS; FRACTURES, BONE; HUMANS; OSTEOPOROSIS; SENSITIVITY AND SPECIFICITY;

EID: 34547561381     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2007.06.010     Document Type: Review

References (53)

1. Allen M., Iwata K., Sato M., and Burr D.B. Raloxifene enhances vertebral mechanical properties independent of bone density. Bone 39 (2006) 1130-1135
2. Balena R., Shih M.-S., and Parfitt. Bone resorption and formation on the periosteal envelope of the ilium: a histomorphometric study in healthy women. J. Bone Miner. Res. 7 (1992) 1475-1482
3. Bauer D.C., Black D.M., Garnero P., Hochberg M., Ott S., Orloff J., et al. Changes in bone turnover and hip non-spine and vertebral fracture in alendronate treated women: the fracture intervention trial. J. Bone Miner. Res. 19 (2004) 1250-1258
4. Brennan T.C., Rybchyn M.S., Conigrave A.D., and Mason R.S. Strontium promotes human osteoblast replication and decreases their osteoclastogenic abilities in primary human osteoblasts. Proceedings of the 28th annual meeting of the Am Soc Bone Mineral Res. Philadelphia USA Sept 15-19 2006. J Bone Miner Res vol. 21(suppl 1) (2006) abst SU 375
5. Boivin G.Y., Chavassieux P.M., Santora A.C., Yates J., and Meunier P.J. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27 (2000) 687-694
6. Bone H.G., Hosking D., Devogelaer J.-P., Tucci J.R., Emkey R.D., Yonino R.P., et al. Ten years experience with alendronate for osteoporosis in postmenopausal women. N. Engl. J. Med. 350 (2004) 1189-1199
7. Boutroy S., Bouxsein M.L., Munoz F., and Delmas P.D.D. In vivo assessment of trabecular microarchitecture by high-resolution peripheral quantitative computed tomography. J. Clin. Endocriol. Metab. 90 (2005) 6508-6515
8. Brown J.P., Delmas P.D., Arlot M., and Meunier P.J. Active bone turnover of the cortico-endosteal envelope in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 64 (1987) 954-959
9. Chapurlat R.D., Palermo L., Ramsay P., and Cummings S.R. Risk of fracture among women who lose bone density during treatment with alendronate. The fracture intervention trial. Osteoporos. Int. 16 (2005) 842-848
10. Civetteli P., Gonnelli S., Zacchei F., Bigazzi S., Vattimo A., Avioli L.V., et al. Bone turnover in postmenopausal osteoporosis: effect of calcitonin treatment. J. Clin. Invest. 82 (1988) 1268-1274
11. Cummings S.R., Karpf D.B., Harris F., Genant H.K., Ensrud K., LaCroix A.Z., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with anti-resorptive drugs. Am. J. Med. 112 (2002) 281-289
12. Cummings SR, Palermo L Browner W, Marcus R, Wallace R Pearson J, Blackwell T, Exkert S, Black D. 2000. Monitoring osteoporosis therapy with bond densitometry: misleading changes and regression to the mean. Fracture intervention trial research group. JAMA 1996; 283: 1318-21.
13. Dawson-Hughes B., Harris S.S., Krall E.A., and Dallal G.E. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. J. Med. 337 (1997) 670-676
14. Delmas P.D. Treatment of postmenopausal osteoporosis. Lancet 359 (2002) 2018-2026
15. Delmas P.D., Licata A.A., Reginster J.Y., Crans G.G., Chen P., Misurski D.A., et al. Fracture risk reduction during treatment with teriparatide is independent of pre-treatment bone turnover. Bone 39 (2006) 237-243
16. Delmas P.D., and Seeman E. Changes in bone mineral density explain little of the reduction in vertebral for non-vertebral fracture risk with anti-resorptive therapy. Bone 34 (2004) 599-604
17. Ericksen E.F., Langdahl B., Vesterby A., Rungby J., and Kassem M. Hormone replacement therapy prevents osteoclastic hyperactivity: a histomorphometric study in early postmenopausal women. J. Bone Miner. Res. 14 (1999) 1217-1221
18. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomised trial. JAMA 282 (1999) 637-645
19. Foldes J., Parfitt A.M., Shih M.-S., Rao D.S., and Kleerekoper M. Structural and geometric changes in iliac bone: relationship to normal aging and osteoporosis. J. Bone Miner. Res. 6 (1991) 759-766
20. Fuchs R.K., Phipps R., and Burr D.B. Reestablishment of normal cancellous bone turnover differs following the withdrawal of alendronate and risedronate treatment in ovariectomized rats. Proceedings of the 27th annual meeting of the Am Soc Bone Mineral Res. Nashville USA Sept 23-27. J. Bone Miner. Res. vol. 20 (suppl 1) (2005) abst SA 415
21. Gonnelli S., Cepollaro C., Pondrelli C., Martini S., Monaco R., and Gennari C. The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis. J. Bone Miner. Res. 12 (1997) 624-631
22. Gonnelli S., Cepollaro C., Pondrelli C., Martini S., Montagnani A., Monaco R., et al. Bone turnover and the response to alendronate treatment in postmenopausal osteoporosis. Calcif. Tissue Int. 65 (1999) 359-364
23. Greenspan S., Sebba A., Saag K., Thompson D., Rosenberg E., Chen E.E., et al. Early reductions in bone turnover markers are associated with 24-month bone mineral density response and non-response in the Fosemanx Actonel Comparison Trial (FACT). Proceedings of the 28th annual meeting of the Am Soc Bone Mineral Res. Philadelphia USA Sept 15-19. J Bone Miner Res 21(suppl 1) (2006) abst [M345]
24. Guyatt G.H., Crabbey A., Griffith L., Walters S., Krolicki N., Favus M., et al. Summary of meta analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol. Metab. Clin. N. Am. 31 (2002) 656-670
25. Heaney R.P., Yates A.J., and Santora A.C. Bisphosphonate effects and the remodelling transient. J. Bone Miner. Res. 12 (1997) 1143-1151
26. Hernandez C.J., Gupt A., and Keaveny T.M. A biomechanical analysis of the effects of resorption cavities on cancellous bone strength. J. Bone Miner. Res. 21 (2006) 1248-1255
27. Hillier T.A., Stone K.L., Bauer D.C., Rizzo J.H., Pedula K.L., Cauley J.A., et al. Evaluating the value of repeat bone mineral density measurement and prediction of fractures in older women: the study of osteoporotic fractures. Arch. Intern. Med. 167 (2007) 155-660
28. Hochberg M.C., Greenspan S., Wasnich R.D., Miller P., Thompson D.E., and Ross P.D. Changes in bone density and turnover explain the reductions in incidence of non-vertebral fractures that occur during treatment with anti-resorptive agents. J. Clin. Endocrinol. Metab. 87 (2002) 1586-1592
29. Hosking D., Chilvers C.E.D., Christiansen C., Ravn P., Wasnich R., Ross P., et al. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. New Engl. J. Med. 338 (1998) 485-492
30. Iwata K., Li J., Follet H., Phipps R.J., and Burr D.B. Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia. Bone 39 (2006) 1053-1058
31. Johnell O., Scheel W.H., Lu Y., Reginster J.-Y., Need A.G., and Seeman E. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodelling in postmenopausal women with osteoporosis. J. Clin. Endocriol. Metab. 87 (2002) 985-992
32. Kanis J.A., Oden A., Hohnell O., Caulin F., Bone H., Alexandre J.M., et al. Uncertain future of trials in osteoporosis. Osteoporos. Int. 13 (2002) 443-449
33. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 333 (1995) 1437-1443
34. Li Z., Meredith M.P., and Hoseyni M.S. A method to assess the proportion of treatment effect explained by a surrogate endpoint. Stat. Med. 20 (2001) 3175-3188
35. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr. Rev. 21 (2000) 115-137
36. Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med 350 (2004) 459-468
37. Marie P.J., Hott M., Modrowski D., De Pollack C., Guillemain J., Deloffre P., et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen deficient rats. J. Bone Miner. Res. 8 (1993) 607-615
38. Mashiba T., Hirano T., Turner C.H., Forwood M.R., Johnston C.C., and Burr D.B. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J. Bone Miner. Res. 15 (2000) 613-620
39. McClung M.R., Wasnich R.D., Hosking D.J., Christiansen C., Ravn P., Wu M., et al. Prevention of postmenopausal bone loss: six-year results from the early postmenopausal intervention cohort study. J. Clin. Endocrinol. Metab. 89 (2004) 4879-4885
40. Parfitt A.M. Skeletal heterogeneity and the purposes of bone remodelling: implications for the understanding of osteoporosis. In: Marcus R., Feldman D., and Kelsey J. (Eds). Osteoporosis (1996), Academic, San diego, CA 315-339
41. Parfitt A.M. Morphologic basis of bone mineral measurements: transient and steady state effects of treatment in osteoporosis. Miner. Electrolyte Metab. 4 (1983) 273-287
42. Reid I.R., Ames R.W., Evans M.C., et al. Long term effects of calcium supplementation on bone loss and fractures in postmenopausal women. Am. J. Med. 98 (1995) 331-335
43. Reginster J.Y., Seeman E., De Vernejoul M.C., Adami S., Compston J., Phenekos C., et al. Strontium ranelate reduces the risk of non-vertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study. J. Clin. Endocrinol. Metab. 90 (2005) 2816-2822
44. Rosen C.J., Hochberg M.C., Bonnick S.I., McClung M., Miller P., Broy P., et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomised double blind study. J. Bone Miner. Res. 20 (2005) 141-151
45. Roschger P., Rinnerthaler S., Yates J., Rodan G.A., Fratzl P., and Klaushofer K. Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29 (2001) 185-191
46. Ruff C.B., and Hayes W.C. Sex differences in age-related remodeling of the femur and tibia. J. Orthop. Res. 6 (1988) 886-896
47. Sarkar S., Mitlak B.H., Wong M., Stock J.L., Black D.M., and Harper K.D. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J. Bone Miner. Res. 17 (2002) 1-10
48. Seeman E., and Delmas P.D. Bone quality; the material and structural basis of bone strength. N. Engl. J. Med. 354 (2006) 2250-2261
49. Seibel M.J., Naganathan V., Barton I., and Grauer A. Relationship between pre-treatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J. Bone Miner. Res. 19 (2004) 323-329
50. Watts N.B., Geusens P., Barton P., and Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J. Bone Miner. Res. 20 (2005) 2097-2104
51. Wasnich R.D., Baggar Y.Z., Hosking D.J., McClung M.R., et al. Changes in bone density and turnover after alendronate or estrogen withdrawal. Menopause 11 (2004) 622-630
52. Wasnich R.D., and Miller P.D. Antifracture efficacy of anti-resorptive agents are related to changes in bone density. J. Clin. Endocrinol. Metab. 85 (2000) 231-236
53. Yeni Y.N., Brown C.U., Wang Z., and Norman TL. The influence of bone morphology on fracture toughness of the human femur and tibia. Bone 21 (1997) 453-459